Publication details
Diabetes mellitus a srdeční selhání: úloha inhibitorů SGLT2
| Title in English | Diabetes mellitus and heart failure: the role of SGLT2 inhibitors |
|---|---|
| Authors | |
| Year of publication | 2018 |
| Type | Article in Periodical (without peer review) |
| MU Faculty or unit | |
| Citation | |
| Description | SGLT2 inhibitors - gliflozins were introduced into clinical practice as peroral antidiabetics, acting by increased glucose excretion by urine using the blockade of SGLT2 co transporter, which leads to blockade of glucose reabsorption in kidneys. The first big clinical trial EMPA REG outcome has shown not only the effect on diabetes mellitus but also the effect on decrease of cardiovascular events, especially Heart failure mortality and hospitalizations. A decrease in body weight by 2-3 and a decrease of systolic blood pressure by 3-5 mmHg kg were also new information. The CANVAS trials were presented in 2017 and confirmed this beneficial effect to decrease of hospitalization from heart failure and other CV events. Data form real life - CVD REAL research on more than 300 000 patient all over the world and confirm positive results from clinical trials. |